For a study, researchers sought to examine the oncologic results of robot-assisted radical cystectomy (RARC).

The International Robotic Cystectomy Consortium database underwent a retrospective evaluation. Patients with pT0 following RARC were found and examined. The demographics and pathological results of the data were examined. Recurrence-free survival (RFS), disease-specific survival (DSS), and overall survival (OS) were shown by Kaplan-Meier curves. The factors connected to RFS and OS were found using multivariate stepwise Cox regression models.

There were found to be 471 individuals (18%) who had pT0. The interquartile range (IQR) for age was 60–73, and the median follow-up was 20 months (IQR 6-47). About 37% underwent neoadjuvant chemotherapy, and 5% had pN+ illness. Disease relapse occurred in 7% of patients; 3% of cases were local, and 5% were distant. Pelvis and lungs were the most frequent locations for local and distant recurrences (2% and 1%, respectively). A 5-year RFS, DSS, and OS of 88%, 93%, and 79%, respectively. RFS was linked with age (hazards ratio [HR] 1.05, 95% CI 1.01-1.09, P = 0.02), pN+ve (HR 11.48, 95% CI 4.47-29.49, P<.01), and reoperations within 30 days (HR 5.53, 95% CI 2.08-14.64, P<.01). The following factors were linked to OS: pN+ve (HR 4.37, 95% CI 1.46-13.06, P<.01), chronic renal disease (HR 3.24, 95% CI 1.45-7.23, P<.01), neoadjuvant chemotherapy (HR 0.41, 95% CI 0.18-0.92, P=.03), and reoperations within 30 days (HR 2.64, 95% CI, 1.08-6.43, P=.03).

Although all patients were pT0 at RARC, 5% had pN+ illness, and 7% relapsed. In pT0, node status had the highest correlation with RFS and OS.